The first randomized, double blind, head-to-head study of Aimovig erenumab ) against topiramate in patients with episodic and chronic migraine (HER-MES) achieved superiority in its primary and secondary endpoints Aimovig showed superior tolerability and efficacy against topiramate and provided a….
